**Core Concept**
Myasthenia gravis (MG) is an autoimmune disease characterized by muscle weakness and fatigue, resulting from the breakdown of the neuromuscular junction (NMJ). This condition is caused by the production of autoantibodies against the acetylcholine receptor (AChR) or, less commonly, against muscle-specific kinase (MuSK).

**Why the Correct Answer is Right**
The primary pathogenic mechanism in MG involves the binding of autoantibodies to the AChR, which leads to the receptor's internalization and degradation. This reduces the number of functional AChR available for acetylcholine binding, impairing neurotransmitter-mediated muscle contraction. The decrease in AChR density results in impaired neuromuscular transmission, causing muscle weakness and fatigue.

**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because, although acetylcholinesterase inhibitors are used in the management of MG to increase acetylcholine availability, they are not directly involved in the pathogenesis of the disease.

**Option B:** This option is incorrect because, while botulinum toxin also disrupts neurotransmitter release, its mechanism of action is different from the autoantibody-mediated destruction of AChR in MG.

**Option C:** This option is incorrect because, although muscle damage is a feature of MG, the primary pathogenic mechanism involves the disruption of the NMJ, rather than direct muscle damage.

**Clinical Pearl / High-Yield Fact**
The "fatigue" and "weakness" seen in MG can be differentiated from other neuromuscular conditions by the improvement in symptoms after rest, which allows the AChR to be replenished and neuromuscular transmission to recover.

**Correct Answer: D. Acetylcholine receptor (AChR).**